Tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, is the lead asset. It is a second-gen CD40 inhibitor. There were a number of first-gen anti-CD40 antibodies in ...

Tonix Pharmaceuticals has reported positive topline outcomes from its Phase I single ascending dose study of its crystallisable fragment (Fc)-modified humanised anti-CD40 ligand (CD40L) monoclonal ...

CD40–CD40L signaling may regulate both the initiation and effector phases of B- and T-cell responses, as well as transmigration of activated cells to target tissues. Direct therapy against this ...

Kiniksa’s actions leave it focused on a cardiovascular disease pipeline led by the IL-1 antagonist KPL-387. The program is ...

The two patients received the treatment as part of a UChicago Medicine pilot study focusing on the use of Eledon's anti CD40 ligand (CD40L) antibody tegoprubart (formerly AT-1501) as an ...

Novartis stops liver transplant program after Astellas drug beats its CD40 prospect in phase 2 Despite ... the list of targeted indications for its CD40L monoclonal antibody frexalimab after ...

“Blocking the CD40 Ligand is a critical component of the immunosuppression regimen for effective translation of organ transplant from nonhuman primates into humans. Our anti-CD40L antibody ...

细胞毒性T细胞抗肿瘤免疫应答主要取决于cDC1s的交叉呈递抗原的能力。一旦激活并通过CD40-CD40L相互作用感知到辅助T细胞，cDC1就会提供关键的共刺激配体和细胞因子，以建立和维持CD8+T细胞免疫反应，这种同源T细胞活化的调节过程称为交叉启动。 在癌症小鼠模型 ...